Skip to main content

12-09-2020 | Liraglutide (obesity) | News


Liraglutide gets FDA go-ahead for teens with obesity

Author: Eleanor McDermid


medwireNews: Liraglutide at its 3.0 mg daily dose can now be used for weight management in US adolescents aged 12 to 19 years, following FDA approval.

The lower 1.8 mg/day dose of the glucagon-like peptide 1 receptor agonist is already available for adolescents with type 2 diabetes. The higher dose, used to combat obesity in adults, is now approved for this younger age group based on a trial published in January this year, which showed significant weight reductions with liraglutide 3.0 mg/day versus placebo, in line with the established effect in adults.

To qualify for treatment, adolescents must have a BMI for their age and sex that correspond to 30 kg/m2 or more for adults, and must weigh more than 60 kg.

The FDA notes that 20% of US adolescents are currently considered obese, according to the latest data from the Centers for Disease Control and Prevention.

medwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature Group


Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »